ANI Pharmaceuticals Soars on Blockbuster Performance of New Drug Formulation

ANI Pharmaceuticals has delivered exceptional quarterly results and significantly raised its full-year guidance, propelled by unprecedented market adoption of its recently launched Cortrophin Gel pre-filled syringe. The biopharmaceutical company is experiencing record-breaking new patient starts across multiple therapeutic areas for this innovative product.

The commercial performance of Cortrophin Gel, which received FDA approval in March 2025, has surpassed all expectations since its second-quarter launch. ANI reports extraordinary demand across neurology, rheumatology, nephrology, ophthalmology, pulmonology, and acute gouty arthritis treatments.

These commercial achievements translated directly into outstanding financial metrics announced on August 8. The company posted record quarterly revenue of $211.4 million, representing a 53.1% year-over-year increase. Non-GAAP adjusted EBITDA surged 62.8% to reach $54.1 million.

Key Financial Highlights:
– GAAP earnings per share: $0.36
– Record non-GAAP adjusted earnings per share: $1.80
– Raised full-year revenue guidance to $818–843 million

The remarkable success of Cortrophin Gel accelerates ANI’s expansion in the rare disease segment while validating the company’s strategic direction. Beyond this breakthrough product, ANI continues to strengthen its generics portfolio. The January 2025 FDA approval and subsequent market introduction of Prucalopride tablets—a generic equivalent to Motegrity®—secured 180 days of competitive generic therapy exclusivity.

Should investors sell immediately? Or is it worth buying ANI?

Another significant milestone came in March 2025 with the expanded FDA approval for ILUVIEN, now cleared for treating chronic non-infectious uveitis affecting the posterior segment (NIU-PS). This approval complements ANI’s retina portfolio, which includes YUTIQ.

Operational strength has been reflected in market performance, with shares reaching a 52-week high of $93.00 on August 29 and registering a 45.15% gain over the past twelve months. Market analysts responded by upwardly revising their expectations for the company in late August.

Looking Ahead

Under CEO Nikhil Lalwani’s leadership, ANI Pharmaceuticals will provide further updates at upcoming investor conferences. The company is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, followed by the Morgan Stanley 23rd Annual Global Healthcare Conference the next day.

Concurrently, the company continues to advance its research initiatives. Preclinical data presentations at EULAR 2025 and the initiation of a Phase 4 study investigating Cortrophin Gel for acute gout flare management underscore ANI’s ongoing commitment to the rare disease sector.